Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 06, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
June 05, 2017
Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma
June 05, 2017
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 04, 2017
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Do We Have Adequate Surveillance in Cancer Survivor Care?
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
June 01, 2017
Currently Reading
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults

Surabhi Dangi-Garimella, PhD
According to the study, to be presented at the 2017 American Society of Clinical Oncology Annual Meeting, vaccination resulted in an 88% overall reduction in vaccine-type infections and a 100% reduction among men, in the young adult population.
One of the fastest growing cancers among young men in the United States, the incidence of human papilloma virus (HPV)-positive oropharyngeal cancer can be reduced with a prophylactic vaccine. These are the findings of a collaborative study that will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Data from the National Health and Nutrition Examination Survey (NHANES) found that for the period between 2011 and 2014, the prevalence of oral HPV was 7.3% for adults between age 18 and 69 years and high-risk HPV was 4%. The absence of any specific disease symptoms makes it difficult to identify infected individuals, and, thereby, easier to transmit the disease.

HPV vaccines have been recommended for cancer prevention. The CDC updated its vaccination recommendations late last year, stating that 11- to 12-year-old children should be administered 2 doses of the 9-valent HPV vaccine spaced 6 months apart, and adolescents and young adults, 15 years and older, should be administered 3 doses. The recommendation subsequently gained support from 69 National Cancer Institute–designated cancer centers.

Maura L. Gillison, MD, PhD, a head and neck medical oncologist and molecular epidemiologist at The Ohio State University and study co-author, said during a pre-meeting press cast organized by ASCO that there have not been any trials evaluating whether currently approved vaccines can prevent HPV infections, especially in the younger population. The objective, therefore, “was to evaluate the impact of HPV vaccination on oral HPV infections among young adults in the United States,” she said.

For their present study, the authors used data from the NHANES study, gathered between 2011 and 2014, to retrospectively analyze the impact of a prophylactic vaccination on the incidence of oral HPV infections among US men and women between 18 and 33 years of age (n = 2627). The exposure was the receipt of 1 or more doses (self-reported) of 4 vaccine types: 16, 18, 6, and 11—or not. The authors also examined the percent reduction in infection-prevalence among vaccinated individuals and population-level effectiveness of vaccination.

The authors found that 18.3% of the study cohort reported receiving at least 1 dose of an HPV vaccine prior to age 26. This included 29.2% of women and 6.9% of men. Oral HPV 16/18/6/11 infections were significantly lower in the vaccinated population (0.11%) compared with the unvaccinated individuals (1.61%; P = .008). The impact was even more dramatic among men: 0.00% versus 2.1% (P = .007) in the vaccinated versus the unvaccinated population, respectively. On the other hand, prevalence of non-vaccine HPV was similar between the 2 populations overall (3.98% versus 4.74%; P = .24), the authors noted.

Based on their analysis, the authors estimated an 88% overall reduction in vaccine-type infections and a 100% reduction among men among young adults, the authors concluded.

“The HPV vaccine may reduce oral HPV infections,” Gillison said. “However, clinical trials would be required to demonstrate a cause-effect relation between vaccination and the extent of oral HPV infections.”

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!